Tuesday, April 16, 2019—A new publication for people living with migraine, Migraine Patient Guidelines from The Global Healthy Living Foundation, is available for free download to assist pe…
Tuesday, April 02, 2019—The first patient has been enrolled in a phase 2/3, double-blind, placebo-controlled trial of intranasally administered BHV-3500 (Biohaven Pharmaceutical, New Haven, CT) being…
Wednesday, March 27, 2019—A real-world study revealed that less than half of patients who begin treatment with onabotulinumtoxinA (Botox; Allergan, Madison, NJ) to prevent chronic migraine receive all …
Logan Schneider, MD
March/April 2019—Sleep has a critical role in brain health and is an essential part of improving neurologic care for all of our patients.
Peter McAllister, MD
March/April 2019—There are knowns, unknowns, and bogeymen.
Ari A. Shemesh, MD; and Daniel R. Gold, DO
March/April 2019—Part 1: Untangling the complexity of dizziness and vertigo requires a careful history.
Monday, March 11, 2019—The Food and Drug Administration (FDA) has accepted the new drug application (NDA) for ubrogepant for acute migraine treatment (Allergan, Madison, NJ) and set a 10-month …
Wednesday, March 06, 2019—The Food and Drug Administration (FDA) has granted priority review status to the supplemental biologics license application (sBLA) for galcanezumab-gnlm (Emgality; Eli Lilly a…
